{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21","upperLimit":"48","value":"32"}]}],"title":"Acute GVHD grade 2-4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7","upperLimit":"29","value":"15"}]}],"title":"Acute GVHD grade 3-4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"The cumulative incidence of acute Graft Versus Host Disease (aGVHD). Events were assigned a severity grade using the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v. 4.0; lower values indicate least severe and higher values indicate most severe. Grades 2 - 4 and grades 3 - 4 events are reported. Subjects who receive all 4 doses of carfilzomib at the maximum tolerated dose level will be considered evaluable for endpoint analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered 20 mg/m\\^2 on days 1 and 2; 36 mg/m\\^2 of Carfilzomib on days 6 and 7.","id":"OG000","title":"Dose Level 3 - Maximum Dose Carfilzomib 36 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Subjects who have received all 4 doses of carfilzomib at the maximum tolerated dose (MTD) level (dose level 3, 36 mg/m\\^2): 39 subjects total. Note: three subjects who completed 4 doses of carfilzomib at the MTD during the phase 1 portion of the study were included in phase 2 analysis of the primary outcome measure.","reportingStatus":"POSTED","timeFrame":"At day 180 post-transplant; data collected up to 3 years","title":"Phase II: Cumulative Incidence of Acute GVHD","type":"SECONDARY","unitOfMeasure":"percentage of participants"}